Veterinary and comparative oncology最新文献

{"title":"Neurological Recovery in 14 Cats With Epidural Lymphoma Treated With Chemotherapy.","authors":"Julya Nathalya Felix Chaves, Mathias Reginatto Wrzesinski, Julia da Silva Rauber, Denis Antonio Ferrarin, Marcelo Luis Schwab, Glaucia Denise Kommers, Mariana Martins Flores, Ana Paula da Silva, Angel Ripplinger, Diego Vilibado Beckmann, Alexandre Mazzanti","doi":"10.1111/vco.13061","DOIUrl":"10.1111/vco.13061","url":null,"abstract":"<p><p>The purpose of this study was to evaluate the rate and timing of neurological recovery in cats with epidural lymphoma who were treated with chemotherapy. The study included cats with various degrees of neurological impairment, confirmed diagnosis of lymphoma and spinal cord involvement. At the start of treatment, of the 14 cats diagnosed with lymphoma, 14.3% (n = 2) had ambulatory paraparesis, 14.3% (n = 2) had non-ambulatory paraparesis, 7.1% (n = 1) paraplegia with deep nociception, 50% (n = 7) were paraplegic with absent deep nociception and 14.3% (n = 2) had non-ambulatory tetraparesis. The chemotherapy treatment given was COP in 10 cats, COP and CHOP in 2 cats and CHOP in 2 cats. The number of chemotherapy sessions needed for neurological recovery varied from 1 to 4, with a total of 1-13 sessions per cat. The rate of neurological recovery was satisfactory in 83.3% (10/12) of the cats. This study indicates that cats with epidural lymphoma treated with chemotherapy have an 83.3% likelihood of partial neurological recovery and a 50% chance of full neurological recovery within a period of 7-28 days, regardless of the level of neurological impairment.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"366-376"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impacts of Vincristine and Prednisolone Chemotherapy on the Canine Gut Microbiota in Dogs Undergoing Treatment for Lymphoma.","authors":"Juan Aragon, Annika M Weber, Madison Tipton, Jennifer Thomsen, Hend Ibrahim, Kristen Weishaar, Sangeeta Rao, Jan S Suchodolski, Jonathan Stockman, Elizabeth P Ryan, Nora Jean Nealon","doi":"10.1111/vco.13063","DOIUrl":"10.1111/vco.13063","url":null,"abstract":"<p><p>Chemotherapy can have adverse gastrointestinal effects in dogs and people. The objective of this study was to assess the impact of vincristine and prednisolone/prednisone, as part of a CHOP chemotherapy [cyclophosphamide, hydroxydaunorubicin, oncovin (vincristine) and prednisolone/prednisone] protocol, on gastrointestinal dysbiosis in dogs with lymphoma. We hypothesised the first week of chemotherapy (administration of vincristine and prednisolone/prednisone, VCR/Pred) produces compositional and functional shifts in the canine faecal microbiota that are associated with increased dysbiosis. Faecal samples from canine lymphoma patients (n = 25) were compared for microbiota and metabolites before (pre-chemotherapy) and after the first week of VCR/Pred (post-chemotherapy). A dysbiosis index (DI) was calculated for each dog via quantitative PCR of seven bacterial taxa established for altered ratios in canine gastrointestinal dysbiosis: Faecalibacterium, Turicibacter, Escherichia coli, Streptococcus, Blautia, Fusobacterium and Peptacetobacter hiranonis (formerly Clostridium hiranonis ). There was a significant increase in the DI post-chemotherapy compared to pre-chemotherapy (p = 0.021) concurrent with a significant decrease in faecal P. hiranonis concentrations post-chemotherapy (p = 0.0003). 16S rRNA amplicon sequencing analysis revealed a significant decrease in Enterococcaceae post-chemotherapy (p = 0.013). Targeted faecal lipid profiling identified markers of host and bacterial metabolic dysfunction that were altered following chemotherapy, including significant decreases in arachidonate (p = 0.0015), nervonate (p = 0.027), cholestanol (p = 0.011) and campesterol (p = 0.0035). These findings support that shifts in gut microbiota structure and function may contribute to gastroenteritis in dogs following the first week of VCR/Pred. Gut dysbiosis measures are important for improved treatment options that alleviate gastrointestinal complications associated with chemotherapy in animals and people.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"388-400"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12353578/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis and Classification of Primary Nodal Lymphomas in Dogs: A Consensus of the Oncology-Pathology Working Group.","authors":"Michael O Childress, Anne Avery, Erica Behling-Kelly, Peter Bennett, Laura Brockley, Ryan Dickinson, Kelly Hughes, William C Kisseberth, Laura Marconato, Valeria Martini, Angela McCleary-Wheeler, Lucia Minoli, Peter Rowland, Shane Sills, Luca Aresu","doi":"10.1111/vco.13064","DOIUrl":"10.1111/vco.13064","url":null,"abstract":"<p><p>One of the primary objectives of the Oncology Pathology Working Group (OPWG) is for oncologists and pathologists to collaboratively generate consensus documents to standardise aspects of and provide guidelines for oncologic pathology in veterinary species. Consensus is established through critical review of the peer-reviewed literature relevant to a subgroup's particular focus. In this article, the authors provide a critical review of the current literature regarding methods for the diagnosis and classification of primary nodal lymphomas of dogs, including histopathology, cytopathology, immunophenotyping and assessment of molecular clonality. Knowledge gaps in the current literature and recommendations for future study are also reported. Major conclusions of this consensus include: (1) Histopathology with immunohistochemistry is required for complete diagnosis and classification of nodal lymphomas; (2) Immunohistochemistry and flow cytometry are the most reliable methods of immunophenotyping lymphomas, though neither is clearly superior to the other; (3) Molecular clonality testing should not be used in favour of immunophenotyping assays for classifying lymphomas; and (4) The use of emerging molecular tests for diagnosing lymphomas in the absence of histopathologic, cytopathologic, or immunophenotypic disease characterisation should be restricted to investigational settings until their diagnostic validity and the clinical benefit they confer to patients are more thoroughly characterised. This document represents the opinions of the OPWG and the authors; it does not constitute a formal endorsement by the American College of Veterinary Pathologists or the Veterinary Cancer Society.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"331-345"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378112/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144095346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potent Therapeutic Activity of NEO212 in Preclinical Models of Human and Canine Leukaemia and Lymphoma.","authors":"Thomas C Chen, Steve Swenson, Thu Zan Thein, Radu O Minea, Axel H Schönthal","doi":"10.1111/vco.13066","DOIUrl":"10.1111/vco.13066","url":null,"abstract":"<p><p>Haematological cancer types, such as leukaemia and lymphoma, represent diseases that are life-threatening to canine and human patients alike, and better treatments are needed. We are developing a novel anticancer agent, NEO212, a conjugate of two cancer drugs, the alkylating agent temozolomide (TMZ) and the monoterpene perillyl alcohol (POH). NEO212 has revealed robust therapeutic activity in preclinical tumour models harbouring different human cancer types. In the comparative preclinical study presented here, a two-species (canine and human) and two-cancer (leukaemia and lymphoma) analysis was performed to determine whether the promising therapeutic activity of NEO212 would span species and cancer types. We investigated the activity of NEO212 in human and canine leukaemia and lymphoma cell lines in vitro and in corresponding mouse models in vivo. Our results show that in vitro NEO212 is significantly more potent than TMZ and POH in all cell lines and exerts activity even against strongly TMZ-resistant tumour cells. In vivo, oral NEO212 strikingly extends the survival of mice harbouring human or canine leukaemia or lymphoma cells. At the same time, NEO212 is well tolerated in dogs at dosages higher than those that achieved therapeutic activity in mouse models. Our study introduces NEO212 as a novel oral cancer drug candidate for both human and veterinary oncology applications.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"412-423"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378078/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144080790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcome and Prognostic Factors of Dogs Treated for Infiltrative Lipoma Undergoing Radiation Therapy: A Retrospective Multi-Institutional Study of 29 Cases.","authors":"Arata Matsuyama, Valerie J Poirier, Michelle M Turek, Valeria S Meier, Jessica Lawrence","doi":"10.1111/vco.13065","DOIUrl":"10.1111/vco.13065","url":null,"abstract":"<p><p>Canine infiltrative lipomas are localised and invasive tumours that are commonly treated with surgery and/or radiation therapy (RT). There is limited efficacy data for treatment of infiltrative lipomas, and optimal fractionation strategies remain unclear. We retrospectively assessed the outcomes and prognostic factors in a cohort of dogs that underwent intensity modulated or three-dimensional conformal RT for infiltrative lipoma. Twenty-nine dogs were included from four academic institutions. The median total radiation dose prescribed and delivered was 51 Gy (range = 20-57 Gy). Dose per fraction ranged from 2.4 to 4.2 Gy, with a median of 3 Gy. Median progression-free survival (PFS) was 1483 days; the median overall survival (OS) was 1483 days. Disease progression was documented in four dogs (14%), all of which received less than 51 Gy (range = 20-50 Gy). Grade V adverse events (AEs) or secondary malignancies were recorded in six dogs (21%; two bones, one skin, one lungs, one urethra and one small intestine AE); assigned attribution was definite (n = 1), probable (n = 2), possible (n = 2) and unlikely (n = 1). Gross tumour volume (GTV) was prognostic for PFS (p < 0.01) while both GTV (p < 0.01) and total radiation dose (p < 0.01) were prognostic for OS (p < 0.01). The number of surgeries and tumour location were not associated with PFS or OS. These findings support the use of RT for long-term local control for unresectable or incompletely excised canine infiltrative lipomas. A higher total radiation dose may result in better long-term local disease control.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"401-411"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143988295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum Lactate Dehydrogenase as a Potential Prognostic Biomarker in Dogs With Appendicular Osteosarcoma.","authors":"Dina Guerra, Silvia Sabattini, Carmit Chalfon, Marina Aralla, Andrea Renzi, Veronica Cola, Stefano Zanardi, Eugenio Faroni, Angela Simonetto, Laura Marconato","doi":"10.1111/vco.13067","DOIUrl":"10.1111/vco.13067","url":null,"abstract":"<p><p>In human medicine, serum lactate dehydrogenase (LDH) is a well-established prognostic marker in osteosarcoma, reflecting tumour burden. This study evaluates serum LDH as a prognostic biomarker in dogs with histologically confirmed appendicular osteosarcoma undergoing a complete staging work-up. Fifty-two dogs with osteosarcoma were prospectively enrolled, and LDH levels were assessed at diagnosis, prior to any treatment. Elevated LDH was observed in 34 (65.4%) dogs. All dogs with distant metastasis had increased LDH levels. A significant association was observed between elevated LDH and metastasis (p = 0.039). To assess the impact of LDH on survival, a subgroup analysis included 38 dogs without metastasis that underwent multimodal treatment and had a minimum follow-up of 180 days. Median time to progression (TTP) and overall survival (OS) were significantly shorter in dogs with elevated LDH (157 and 169 days, respectively) compared to those with LDH within reference limits (252 and 387 days, respectively; p = 0.035 and p = 0.017). On univariable analysis, elevated LDH was the only variable associated with an increased tumour progression risk (HR = 2.26, 95% CI = 1.09-4.69, p = 0.029). Additionally, elevated LDH, absence of immunotherapy administration, and increased serum alkaline phosphatase activity were significantly associated with a higher mortality risk. These findings suggest that elevated LDH at diagnosis indicates a more advanced disease stage and poorer prognosis in dogs with appendicular osteosarcoma. LDH may aid in treatment planning and prognosis assessment. Further studies should confirm these results and explore its combination with other biomarkers to refine prognostic evaluation.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"424-431"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144136352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Decreased Kidney Function in Dogs Receiving Carboplatin: A Retrospective Cohort Study of 98 Dogs (2006-2024).","authors":"Andrew D Yale, Alvina So, Alexandra Guillén, Isabelle Desmas-Bazelle, Francesco Rogato, Rosanne E Jepson","doi":"10.1111/vco.13069","DOIUrl":"10.1111/vco.13069","url":null,"abstract":"<p><p>Decreased kidney function is observed in some people receiving carboplatin, but limited literature explores this in dogs. The aim of this study was to evaluate the incidence and risk factors for decreased kidney function in dogs receiving carboplatin. A single-institute retrospective cohort study compared the incidence of decreased kidney function between non-azotaemic dogs receiving carboplatin and an age- and weight-matched cancer-bearing control group not receiving chemotherapy. Change in creatinine concentration and a linear mixed effects model were used to compare trends in creatinine between groups. Decreased kidney function was defined as a sustained increase in creatinine ≥ 26.5 μmol/L on ≥ 2 consecutive measurements compared to baseline; the VCOG-CTCAE v2 grading system for increased creatinine was also applied. Risk factors were explored. Ninety-eight dogs were included (n = 49/group). There was no difference in median change in creatinine concentration (+2.0 μmol/L; p = 0.311) or creatinine trends (p = 0.958) across the study period between groups. Incidence of decreased kidney function was low and did not significantly differ between groups (carboplatin group n = 4 [8.2%]; control group n = 2 [4.1%]; p = 0.678); no risk factors were identified. There was no difference in the frequency of VCOG grade one (p = 0.731), two (p = 0.641) or three (p = 0.429) creatinine adverse events between groups. Non-azotaemic dogs receiving carboplatin do not have a significantly increased short-term risk of decreased kidney function compared to those not receiving chemotherapy, although the numerical increase in incidence in dogs receiving carboplatin could be clinically relevant. Larger studies should aim to explore this further and investigate carboplatin's impact on subclinical and long-term renal function.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"442-453"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378092/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144226823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vinorelbine as a Rescue Treatment for Canine Histiocytic Sarcoma: A Multicentre Retrospective Study of 18 Dogs.","authors":"Nina Vigevani, Carmit Chalfon, Alexandra Guillén, Laura Marconato, Isabel Amores-Fuster, Jean-Benoit Tanis, Riccardo Finotello","doi":"10.1111/vco.13060","DOIUrl":"10.1111/vco.13060","url":null,"abstract":"<p><p>Histiocytic sarcoma (HS) is a highly metastatic cancer, and while response to several chemotherapy agents has been studied, the outcome remains poor. Vinorelbine (VNB) has been considered a possible treatment option, but data are limited. The aim of this study was to assess the efficacy and toxicity of VNB in canine HS. Medical records of dogs with HS, treated with VNB as first-line or rescue treatment, were reviewed. Overall response rate (ORR), progression-free survival (PFS), overall survival post-VNB (post.VNB.OST) and adverse events were evaluated. Associations between outcome measures and signalment, disease extent/location, diagnostic modality and response to previous chemotherapies were analysed. Eighteen dogs were included: 12 disseminated and six localised HS. VNB was a rescue treatment in all dogs. ORR was 38.9% [two complete responses (CR), five partial responses (PR)] including two dogs showing delayed best responses. Median PFS and post-VNB-OST for all dogs were 49 (95% CI: 33-166) and 75.5 days (95% CI: 55-174), respectively. Responders showed significantly longer median PFS (120 days) compared to non-responders (41 days). None of the other factors analysed were associated with ORR, PFS and post-VNB-OST, including pulmonary location. Neutropenia and gastrointestinal toxicity were common; however, the majority were low-grade with no hospitalisation required. Vinorelbine can be an effective and safe treatment for canine HS; disease location alone may not be a key predictive factor for VNB response and outcome. Further prospective studies on larger cohorts are required to confirm these findings.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"358-365"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144021019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transferrin Receptor-1: Expression in Canine Mammary Tumours and In Vitro Therapeutic Applications.","authors":"Valentina Moccia, Nicolò Rensi, Giovanni Paolo Marullo, Alessandro Sammarco, Federico Bonsembiante, Filippo Torrigiani, Lucia Salvioni, Davide Prosperi, Valentina Zappulli, Laura Cavicchioli","doi":"10.1111/vco.70000","DOIUrl":"10.1111/vco.70000","url":null,"abstract":"<p><p>The transferrin receptor-1 (TFR-1) is overexpressed in many types of human cancers and, in recent years, several studies have investigated its use as a preferential channel for drug cellular uptake in cancer therapy. In veterinary medicine, TFR-1 expression in cancer cells and tissues has been poorly described, as well as its therapeutic potential. In this study we investigated TFR-1 expression in different subtypes of canine mammary tumours (CMTs) and in two CMT cell lines, one primary (CIPp) and one metastatic (CIPm). Additionally, we also compared the in vitro efficacy of an engineered human apoferritin nanocage loaded with doxorubicin (HFn(DOX)) with the conventional doxorubicin treatment on CIPp and CIPm. In CMT tissues, TFR-1 was more expressed in the tumoral tissues compared to the hyperplastic counterparts, specifically with regards to carcinoma and malignant myoepithelioma and simple carcinoma subtypes (p < 0.05). CIPp and CIPm did not show any significant difference in TFR-1 protein expression, while TFR-1 gene expression was higher in CIPm (p < 0.05). The treatment with HFn(DOX) was more efficient than free doxorubicin only on CIPp at high concentrations (50 μM). In conclusion, we show for the first time the variability of TFR-1 expression in CMT tissues and cell lines. Although further investigations are necessary, HFn can be loaded with different chemotherapeutic compounds, becoming an innovative therapeutic tool for the treatment of cancers highly expressing TFR-1 in veterinary and human medicine.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"476-485"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378079/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144476913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective Study Evaluating Outcomes Following Palliative Radiotherapy With or Without Chemotherapy for Dogs With Presumed Cardiac Hemangiosarcoma.","authors":"Cory N Wakamatsu, Brianna M Potter, Del Leary, Mary-Keara Boss, Tiffany W Martin","doi":"10.1111/vco.13068","DOIUrl":"10.1111/vco.13068","url":null,"abstract":"<p><p>Canine cardiac hemangiosarcoma (cHSA) represents a complex clinical challenge in that those afflicted have an acute risk of death due to cardiac tamponade and high morbidity and mortality given the frequency of metastasis. Previous studies show that radiation therapy (RT) can decrease the risk of tamponade; however, an optimal approach has yet to be determined. The objective of this study was to evaluate the outcomes of dogs with presumptive cHSA treated with varied RT protocols and modalities, and to contrast findings with previously published literature. Secondary objectives were to assess differences in outcomes between those that received chemotherapy post-RT or did not, single fraction versus multiple-fraction RT protocols, and CT-guided versus manually calculated treatment plans. Twenty-seven dogs with echocardiographic evidence of an atrial or auricular cardiac mass that received RT were included. The frequency of pericardiocentesis before and post-RT were compared. Overall survival time was determined, along with survival time specific to those that received chemotherapy, were treated with CT-based radiation plans, and were prescribed a single fraction versus multiple fractions. Pericardiocentesis was performed an average of 1.1 times per week before RT, and an average of 0.18 times per week after RT (p = 0.01). Median overall survival time was 137 days. Plans made without CT guidance were associated with more adverse radiation events, but all were minimally impactful on quality of life. Most dogs died or were euthanized due to metastatic disease. This study shows similar benefits to previously published data in a larger cohort of dogs using a less-conformal radiation modality. As well, it highlights future directions to identify optimal systemic therapies to delay the onset of metastasis.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":"432-441"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378083/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144183153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}